{"id":"NCT00640601","sponsor":"AstraZeneca","briefTitle":"Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia","officialTitle":"A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2008-03-21","resultsPosted":"2012-06-22","lastUpdate":"2012-06-25"},"enrollment":331,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Quetiapine Fumarate Extended- Release","otherNames":["Seroquel XR®"]}],"arms":[],"summary":"A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.","primaryOutcome":{"measure":"Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study","timeFrame":"Baseline to 24 weeks (or end of study)","effectByArm":[{"arm":"Seroquel XR","deltaMin":56.88,"sd":0.508}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":25},"locations":{"siteCount":36,"countries":["Australia","Canada","Hong Kong","South Korea"]},"refs":{"pmids":["23281876"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":295},"commonTop":["Somnolence","Dizziness","Sedation","Dry Mouth","Anxiety"]}}